SAN.PA - Sanofi

Paris - Paris Delayed price. Currency in EUR
65.71
0.00 (0.00%)
As of 5:35PM CEST. Market open.
Stock chart is not supported by your current browser
Previous close65.71
Open65.22
Bid71.12 x 1000
Ask71.74 x 44000
Day's range65.20 - 66.03
52-week range25.38 - 87.65
Volume4,253,062
Avg. volume7,491
Market cap81.975B
Beta0.84
PE ratio (TTM)9.87
EPS (TTM)6.66
Earnings date27 Apr 2018
Forward dividend & yield3.03 (4.59%)
Ex-dividend date2018-05-11
1y target est79.19
  • GlobeNewswire2 hours ago

    Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

    Paris - 24th April 2018   -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

  • Globe Newswire2 hours ago

    Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

    Paris - 24th April 2018  -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011.

  • Motley Fool3 days ago

    Why Dicerna Rocketed Higher Today

    Investors are happy the biotech ended a lawsuit hanging over its head.

  • Reuters - UK Focus4 days ago

    Generics group Alvogen puts Eastern European ops up for sale -sources

    Generics firm Alvogen is putting its Central and Eastern European (CEE) operations up for sale as its private equity owners seek a step-by-step exit from the maker of drugs against cancer, heart and lung diseases, people close to the matter said. Buyout group CVC (Taiwan OTC: 4744.TWO - news) and Singapore state fund Temasek, which bought a controlling stake in Alvogen in 2015 at a valuation of $2 billion, have asked investment bank Jefferies to find a buyer for Alvogen's CEE business, which may be valued at up to $1 billion, they added. CVC and Jefferies declined to comment, Temasek was not immediately available for comment.

  • Sanofi to Divest European Generic Unit, Streamline Business
    Zacks5 days ago

    Sanofi to Divest European Generic Unit, Streamline Business

    Sanofi (SNY) announces sale of its European generic unit, Zentiva, for $2.4 billion.

  • Reuters - UK Focus5 days ago

    AI drug hunter BenevolentAI worth $2 bln after fund raising

    BenevolentAI, a British drug developer that uses artificial intelligence to identify new medicine candidates, said it had raised $115 million in a funding round that valued it at $2 billion. The company, which has more than 20 drugs in development, plans to use the funds to increase the scale of its activities and broaden the disease areas on which it focuses. BenevolentAI has grown rapidly since it was founded in 2013, mirroring growing interest across the pharmaceuticals industry in harnessing the power of AI to speed up drug discovery and development.

  • Reuters6 days ago

    Sanofi's CFO Contamine to retire later this year

    PARIS (Reuters) - Sanofi's (SASY.PA) executive vice president and chief financial officer, Jerome Contamine, plans to retire later this year, the French drugmaker said on Tuesday. In an emailed statement, ...

  • Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
    Bloomberg7 days ago

    Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker

    Sanofi Chief Financial Officer Jerome Contamine is planning to step down from the French drugmaker later this year after almost a decade in the job.

  • The Wall Street Journal7 days ago

    [$$] Advent in Exclusivity to Buy Czech Drugmaker Zentiva for €1.9 Billion

    The firm has presented a €1.9 billion ($2.35 billion) binding offer for the drugmaker.

  • In Pharma, If You Can't Join Them, Beat Them
    Bloomberg7 days ago

    In Pharma, If You Can't Join Them, Beat Them

    Advent is preparing to take on a drugmaker it tried and failed to buy.

  • Reuters7 days ago

    Bank trio expected to lead financing on Zentiva sale

    Goldman Sachs, JP Morgan and Morgan Stanley are expected to lead a debt financing totalling in excess of €1bn backing private equity firm Advent International’s acquisition of French healthcare group Sanofi’s (SASY.PA) European generics drugs arm Zentiva, banking sources said. Sanofi entered exclusive talks to sell Zentiva to Advent for €1.9bn, including equity and debt, the companies said on Tuesday.

  • Reuters7 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 billion

    French healthcare group Sanofi is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • Reuters - UK Focus7 days ago

    Sanofi in talks to sell generics arm to Advent for $2.4 bln

    French healthcare group Sanofi (LSE: 0O59.L - news) is in exclusive talks to sell its Zentiva European generics drugs arm to private equity firm Advent International for 1.9 billion euros ($2.4 billion), the companies said on Tuesday. Sanofi said the sale was expected to be completed before the end of the year, and Advent's offer was binding and fully financed. The 1.9 billion euros price is an enterprise value, including equity and debt.

  • The Wall Street Journal7 days ago

    [$$] Sanofi in Talks With Advent to Sell Zentiva

    Sanofi said it has entered exclusive talks to sell its European generic business Zentiva to Advent International for €1.92 billion.

  • Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
    Bloomberg7 days ago

    Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech

    Sanofi plans to sell its European generic-drug unit to buyout firm Advent International Corp. for 1.9 billion euros ($2.4 billion) as part of a broader move by Chief Executive Officer Olivier Brandicourt ...

  • GlobeNewswire7 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi`s European generics business Advent to invest in Zentiva to ...

  • Globe Newswire7 days ago

    Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

    Divestiture of European generics, a non-core business, is part of Sanofi's strategy to simplify and reshape the Company. Transaction anticipated before end of the year, following consultation with Sanofi employees' representatives and subject to customary closing conditions.

  • The Wall Street Journal8 days ago

    [$$] Charterhouse Portfolio Company Closes Sanofi Deal

    Cooper-Vemedia paid €158 million ($194.8 million) for 12 pharmaceutical brands.

  • Reuters8 days ago

    France's Sanofi sells 12 brands to Charterhouse's Cooper-Vemedia

    French healthcare and drugs group Sanofi (SASY.PA) has agreed to sell a portfolio of 12 pharmaceutical brands to Charterhouse Capital Partners' Cooper-Vemedia drugs manufacturing arm for 158 million euros (£136.6 million), the companies said on Monday. Sanofi said the sale formed part of its strategy to focus on its main businesses in areas such as allergy treatments and nutritional products, and to simplify its business portfolio. Private equity and investment firm Charterhouse Capital said the acquisition would help build up the healthcare portfolio of Cooper-Vemedia, which is a European drug manufacturer and distributor.

  • Advent Is Said to Near Deal to Acquire Sanofi Generics Unit
    Bloomberg8 days ago

    Advent Is Said to Near Deal to Acquire Sanofi Generics Unit

    Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said.

  • GlobeNewswire12 days ago

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général ...

  • Globe Newswire12 days ago

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

    Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l'Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,506,080,598 €Registered office : 54, rue La Boétie - 75008 Paris - FranceRegistered at the Paris Commercial and Companies Registry under number 395 030 844 Date   Total number of issued shares   Number of real voting ...

  • Reuters - UK Focus12 days ago

    Takeda sounds out banks for loans as it moves towards Shire bid -sources

    Takeda Pharmaceutical has sounded out its major creditors for loans, two sources with direct knowledge of the matter said, as it moves closer to a bid for London-listed rare disease specialist Shire that could hit $50 billion. Expectations that Japan's largest drugmaker by sales will bid for Shire before an April 25 deadline have mounted since its chief executive Christophe Weber discussed the strategic case for the deal at a briefing with analysts last week. Buying Shire would be transformational for Takeda but would be a huge financial stretch, since the company is worth around $10 billion more than the Japanese group.

  • GlobeNewswire12 days ago

    Sanofi to invest €350 million in Canadian vaccine facility

      Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) Sanofi to invest €350 million in Canadian vaccine facility   Expansion demonstrates company`s commitment to innovation and leadership in global ...

  • Globe Newswire12 days ago

    Sanofi to invest €350 million in Canadian vaccine facility

    April 12, 2018 - Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company's Canadian operations and its commitment to advancing public health around the world.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes